Olema Pharmaceuticals, Inc.
OLMADrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
OLMA Earnings Report
EPS Est: $-0.53 | FQ end 2026-06
How OLMA's past catalysts played out
Palazestrant
Breast Cancer
Ribociclib
Breast Cancer
OP-1250
Hormone Receptor Positive Breast Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Palazestrant | Phase 3 | Breast Cancer | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
OP-1250 | Phase 2 | Hormone Receptor Positive Breast Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Olema Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Olema Pharmaceuticals, Inc.'s (OLMA) pipeline across Phase 3, Phase 2. Its lead program is Palazestrant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Olema Pharmaceuticals, Inc.'s next FDA catalyst?→
Olema Pharmaceuticals, Inc.'s (OLMA) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OLMA biotech catalysts?→
Add OLMA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Olema Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.